Touloumi G, Karafoulidou A, Gialeraki A, Katsarou O, Milona I, Kapsimali V, Mandalaki T, Hatzakis A
Department of Hygiene and Epidemiology, Athens University Medical School, Greece.
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):89-97. doi: 10.1097/00042560-199809010-00014.
Our objectives are to describe the progression of HIV disease and to assess the influence of hemophilia-related variables, age at infection, and antibodies to cytomegalovirus infection (anti-CMV) in a Greek cohort of 158 HIV-1-positive hemophilic men, who received prospective follow-up for up to 16 years after infection. A total of 79 patients had died, representing a cumulative progression rate of 72.4% (95% confidence interval [CI], 56.6-83.3). A significant proportion of the mortality (30%) resulted from conditions not formally related to AIDS, with liver failure and cerebral hemorrhage predominant. At 16 years after seroconversion, 66 patients had developed clinical AIDS, a cumulative progression rate of 58.2% (95% CI, 47.1%-86.3%) whereas 15 years after infection 81.5% (95% CI, 74.2%-87.9%) of the patients had AIDS or a CD4 cell count <200 cells/mm3. Hemophilia-related variables or presence of anti-CMV were not significantly associated with disease progression. Age at infection was a strong prognostic factor for all three endpoints. Appropriate modeling showed a nonlinear age effect, with a steeper increase of relative hazard for patients >40 years of age at seroconversion. The age effect remained significant even after controlling for current CD4 cell count. Further investigation is required to elucidate the mechanisms of the age effect and the contribution of HCV coinfection on the disease progression.
我们的目标是描述HIV疾病的进展情况,并评估在一个由158名HIV-1阳性血友病男性组成的希腊队列中,血友病相关变量、感染时年龄以及巨细胞病毒感染抗体(抗CMV)的影响。这些患者在感染后接受了长达16年的前瞻性随访。共有79名患者死亡,累积进展率为72.4%(95%置信区间[CI],56.6 - 83.3)。相当一部分死亡率(30%)是由与艾滋病无直接关联的疾病导致的,其中肝衰竭和脑出血最为常见。血清转化后16年,66名患者发展为临床艾滋病,累积进展率为58.2%(95% CI,47.1% - 86.3%);而感染后15年,81.5%(95% CI,74.2% - 87.9%)的患者患有艾滋病或CD4细胞计数<200个细胞/mm³。血友病相关变量或抗CMV的存在与疾病进展无显著关联。感染时年龄是所有三个终点的强有力预后因素。合适的模型显示年龄效应呈非线性,血清转化时年龄>40岁的患者相对风险增加更为陡峭。即使在控制了当前CD4细胞计数后,年龄效应仍然显著。需要进一步研究以阐明年龄效应的机制以及丙型肝炎病毒合并感染对疾病进展的影响。